Navigation Links
Senesco Technologies Initiates Preclinical Studies for Cancer Target
Date:12/5/2007

NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today, that it has initiated preclinical lab studies at Mayo Clinic focused on multiple myeloma. These studies will further test the ability of Senesco's Factor 5A gene technology to up-regulate apoptosis of cancer cells. Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.

The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to the Food and Drug Administration for an Investigational New Drug Application.

Previously, Senesco has announced the results of experiments performed at Mayo Clinic on a human multiple myeloma cell line. In those experiments, treatment with Factor 5A caused significant increase in apoptosis of the cancer cells compared to the untreated cells.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2018)... ... ... The International Society of Hair Restoration (ISHRS) recently held the 26th ... The event, held in Hollywood, California from October 10th-14th, was chaired by Dr. Parsa ... founder of Parsa Mohebi Hair Restoration in Los Angeles, “my first step ...
(Date:11/17/2018)... (PRWEB) , ... November 17, 2018 , ... Dr. Sundardas, ... lead you through a path of discovery finding your vision and clarity about your ... toward reaching your goals, expanding your productivity, purpose, and the joy in your life. ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... addition of University Veterinary Specialists (UVS), now known as MedVet Pittsburgh. The City ... MedVet looks forward to providing local veterinarians continued support and access to specialty ...
Breaking Medicine Technology:
(Date:11/16/2018)... CLARA, Calif. (PRWEB) , ... November 16, 2018 ... ... has announced the launch of a new corridor from Canada to India. The ... Kingdom. , According to the Canadian International Development Platform, in 2016, an estimated ...
(Date:11/16/2018)... ... ... Opioid drugs are commonly prescribed for back pain and other chronic pain. They work by ... problem with these drugs, however, is that they are very addictive. In fact, statistics from ... more than 130 people per day died as a result of opioid drug overdose. ...
(Date:11/15/2018)... BOTHELL, Wash. (PRWEB) , ... November 15, 2018 ... ... natural health and cosmetic benefits of acupuncture available to people in an accessible ... growing health and wellness franchise in the nation, opening locations all across the ...
(Date:11/15/2018)... ... 15, 2018 , ... Sift Healthcare, a revenue cycle intelligence ... investors including Wind River Financial, a Madison-based payment processing company. , The ... to provide a range of solutions for healthcare organizations including claims workflow intelligence, ...
(Date:11/15/2018)... ... November 15, 2018 , ... Drs. Randolph ... skilled medical professionals to join their team at Waldman, Schantz, Turner ... clinic, Skin Chic, and is expanding its staff to meet patient demand. These ...
Breaking Medicine News(10 mins):